A Replicate Phase III Clinical Trial to Assess the Reproducibility of Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Participants With Seasonal Allergic Conjunctivitis (AC) Using the Environmental Exposure Chamber (EEC)
Reproxalap is a reactive aldehyde species inhibitor which demonstrated good safety and significant reduction in AC signs/symptoms in the first Phase III study conducted from 2019-2021 (NCT04207736). A replicate phase III study was conducted in 2021-2023 in an EEC, to confirm the reproducibility of Reproxalap ’s efficacy (NCT05234554).
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Anne Marie Salapatek, Yasmeen Goyal, Christy Fredrick, Gaayathrry Thurairajah, Patricia Couroux, Todd Brady Source Type: research
More News: Allergy | Allergy & Immunology | Clinical Trials | Conjunctivitis | Environmental Health | Opthalmology | Study